Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 9/20 | 0.46 |
| ▸ | WNT1 | P04628 | 8/20 | 0.46 |
| ▸ | PIM1 | P11309 | 5/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | CLK3 | P49761 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397113 | 0.89 | LRRK2 (0.47) | DYRK1AWNT1PIM1LRRK2MAPKAPK2 | |
| SCHEMBL2398394 | 0.81 | DYRK1A (0.47) | DYRK1AWNT1PIM1LRRK2CLK2 | |
| SCHEMBL2398692 | 0.78 | CNR2 (0.48) | PIM1LRRK2 | |
| SCHEMBL1559214 | 0.75 | MAPK10 (0.46) | LRRK2MAPKAPK2 | |
| SCHEMBL2397132 | 0.75 | DYRK1A (0.44) | DYRK1AWNT1LRRK2MAP4K1CLK2 | |
| SCHEMBL1558709 | 0.74 | NPBWR1 (0.46) | — | |
| SCHEMBL2400727 | 0.74 | LRRK2 (0.48) | DYRK1AWNT1LRRK2IRAK4CLK2 | |
| SCHEMBL2396513 | 0.74 | LRRK2 (0.53) | PIM1LRRK2MAP4K1 | |
| SCHEMBL2398645 | 0.74 | LRRK2 (0.42) | DYRK1AWNT1LRRK2CLK2CLK3 | |
| SCHEMBL1559133 | 0.73 | MAP3K5 (0.40) | PIM1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212053-A1 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PIK3CA, AKT1, PIK3R5 | DYRK1A 360/4885WNT1 1222/4885PIM1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.